Illumina had filed a series of suits against several companies in the UK starting in 2015, which were recently consolidated into one case.

The authorization implements regulatory strategies the FDA advanced with industry stakeholders, though labs may still be more inclined to take the CLIA route, as long as it is available.

The government payor made some adjustments in finalizing the 2018 clinical lab fee schedule, but the industry continues to feel CMS is ignoring its most salient concerns.

Labs reported on their work with kits from both Roche and Thermo Fisher, both of which have launched new commercial liquid biopsy products in recent years.

Validation results presented at the Association for Molecular Pathology meeting demonstrate that the test can be implemented clinically, replacing existing FISH and PCR assays.

In Nucleic Acids Research this week: pipeline to analyze and visualize bacterial genomes, database of global set of human genomes, and more.

Researchers test gene therapy targeting a different cancer protein in a new trial, the New York Times reports.

Pennsylvania State University researchers found that salivary microRNAs could predict which kids would have longer concussion symptoms, according to NPR.

The Associated Press reports Alex Azar, the new Department of Health and Human Services secretary nominee, made millions of dollars as a pharmaceutical executive.

Next-generation sequencing (NGS) continues to revolutionize personalized medicine as NGS technology improves and costs continue to fall, resulting in an increased number of scientific and health-related applications. However, the success of a sequencing project rests on the sample quality and NGS library used to generate the data. Poor quality libraries will produce poor quality or biased sequencing data that can slow the advancement and clinical utility of this great new technology.